162 related articles for article (PubMed ID: 30416780)
1. A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification.
Zhu H; Wang C; Wang J; Chen D; Deng J; Deng J; Fan J; Badakhshi H; Huang X; Zhang L; Cai J; Guo S; Qian W; Nie Y; Li Q; Zhao K
J Thorac Dis; 2018 Sep; 10(9):5328-5338. PubMed ID: 30416780
[TBL] [Abstract][Full Text] [Related]
2. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M
J Exp Clin Cancer Res; 2017 Aug; 36(1):101. PubMed ID: 28764725
[TBL] [Abstract][Full Text] [Related]
3. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas.
Yang YL; Xu KL; Zhou Y; Gao X; Chen LR
Chin Med J (Engl); 2012 Feb; 125(3):450-4. PubMed ID: 22490401
[TBL] [Abstract][Full Text] [Related]
4. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.
Fukuoka S; Kojima T; Koga Y; Yamauchi M; Komatsu M; Komatsuzaki R; Sasaki H; Yasunaga M; Matsumura Y; Doi T; Ohtsu A
Oncotarget; 2017 Feb; 8(7):11020-11029. PubMed ID: 28038457
[TBL] [Abstract][Full Text] [Related]
5. NIR-II Navigation with an EGFR-Targeted Probe Improves Imaging Resolution and Sensitivity of Detecting Micrometastases in Esophageal Squamous Cell Carcinoma Xenograft Models.
Wang L; Liang M; Xiao Y; Chen J; Mei C; Lin Y; Zhang Y; Li D
Mol Pharm; 2022 Oct; 19(10):3563-3575. PubMed ID: 35420035
[TBL] [Abstract][Full Text] [Related]
6. EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab.
Wang X; Fu R; Hu Y; Du H; Li S; Li Z; Liu Y; Li Q; Zhang L; Ji J
Oncol Rep; 2017 Oct; 38(4):2387-2393. PubMed ID: 28849161
[TBL] [Abstract][Full Text] [Related]
7. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
[TBL] [Abstract][Full Text] [Related]
8. Resistance to cetuximab in EGFR-overexpressing esophageal squamous cell carcinoma xenografts due to FGFR2 amplification and overexpression.
Zhang Y; Pan T; Zhong X; Cheng C
J Pharmacol Sci; 2014; 126(1):77-83. PubMed ID: 25242085
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma.
Lin G; Sun XJ; Han QB; Wang Z; Xu YP; Gu JL; Wu W; Zhang GU; Hu JL; Sun WY; Mao WM
Oncol Lett; 2015 Aug; 10(2):901-906. PubMed ID: 26622592
[TBL] [Abstract][Full Text] [Related]
10. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
Sato F; Kubota Y; Natsuizaka M; Maehara O; Hatanaka Y; Marukawa K; Terashita K; Suda G; Ohnishi S; Shimizu Y; Komatsu Y; Ohashi S; Kagawa S; Kinugasa H; Whelan KA; Nakagawa H; Sakamoto N
Cancer Biol Ther; 2015; 16(6):933-40. PubMed ID: 25897987
[TBL] [Abstract][Full Text] [Related]
11. A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.
Zhang L; Yang J; Cai J; Song X; Deng J; Huang X; Chen D; Yang M; Wery JP; Li S; Wu A; Li Z; Li Z; Liu Y; Chen Y; Li Q; Ji J
Sci Rep; 2013 Oct; 3():2992. PubMed ID: 24141978
[TBL] [Abstract][Full Text] [Related]
12. Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance.
Liu Z; Chen Z; Wang J; Zhang M; Li Z; Wang S; Dong B; Zhang C; Gao J; Shen L
J Hematol Oncol; 2018 Aug; 11(1):109. PubMed ID: 30157900
[TBL] [Abstract][Full Text] [Related]
13. PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma Models.
Lee TS; Song IH; Shin JI; Park YS; Kim JY; Kim KI; Lee YJ; Kang JH
Cells; 2018 Oct; 7(11):. PubMed ID: 30373221
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma.
Hong MH; Heo SG; Lee YG; Kim HS; Park KU; Kim HG; Ko YH; Chung IJ; Min YJ; Kim MK; Kim KR; Yoo J; Kim TM; Kim HR; Cho BC
Cancer; 2020 Oct; 126(20):4521-4531. PubMed ID: 32749686
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.
De Cesare M; Lauricella C; Veronese SM; Cominetti D; Pisano C; Zunino F; Zaffaroni N; Zuco V
Clin Cancer Res; 2014 Feb; 20(4):995-1006. PubMed ID: 24327272
[TBL] [Abstract][Full Text] [Related]
17. EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models.
Koi L; Löck S; Linge A; Thurow C; Hering S; Baumann M; Krause M; Gurtner K
Radiother Oncol; 2017 Sep; 124(3):496-503. PubMed ID: 28807520
[TBL] [Abstract][Full Text] [Related]
18. Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues.
Zhang G; Zhang Q; Zhang Q; Yin L; Li S; Cheng K; Zhang Y; Xu H; Wu W
J Cancer Res Clin Oncol; 2010 Apr; 136(4):587-94. PubMed ID: 19823871
[TBL] [Abstract][Full Text] [Related]
19. Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer.
Guo K; Wang WP; Jiang T; Wang JZ; Chen Z; Li Y; Zhou YA; Li XF; Lu Q; Zhang LJ
J Thorac Dis; 2016 Jul; 8(7):1753-63. PubMed ID: 27499966
[TBL] [Abstract][Full Text] [Related]
20. FOXP3 expression in esophageal squamous cell carcinoma : Implications for cetuximab sensitivity and therapeutic strategies.
Wu S; Wang Y; Xiao Z; Zhang J; He Z; Ye M
Wien Klin Wochenschr; 2024 Jun; 136(11-12):331-339. PubMed ID: 37874348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
